The move comes after two health workers from the US charity Samaritan's Purse were treated with medication that the WHO said had never been tested and shown to be safe in people.
"We are in an unusual situation in this outbreak. We have a disease with a high fatality rate without any proven treatment or vaccine," said Marie-Paule Kieny, assistant director-general of the UN health agency.
"We need to ask the medical ethicists to give us guidance on what the responsible thing to do is," she said in a statement.
The patients, who were rushed to the United States amid tight medical security, were reportedly given an experimental drug known as ZMapp.
Both have shown improvements in their health and are now being treated in isolation at an Atlanta, Georgia hospital.
There is currently no registered medicine or vaccine against the Ebola virus -- which in the past has shown fatality rates approaching 90 percent -- but there are several experimental options under development.
The WHO said experimental drugs raised questions about whether they should be deployed during such an outbreak and, given the extremely limited amount available, who should receive them if they were used.
"The guiding principal with use of any new medicine is 'do no harm'. Safety is always the main concern," it added.
The Ebola virus causes fever, vomiting, diarrhoea, muscle aches and sometimes organ failure and hemorrhaging.
The ongoing outbreak in West Africa is the deadliest in history, having killed 932 of the more than 1,700 infected.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
